This activity is expired and is no longer available for CME credit.


Results from the Restore Extension Study of Ranibizumab for DME

Release Date: 6/6/2012Expiration Date: 6/5/2015
Credit Type: CME / ParticipationNumber of Credits: 0
Content Type: Provider:
The AEs reported in the interim analysis were consistent with the published safety profile of RBZ in DME. Overall, an average of 3.8 RBZ injections was sufficient to maintain BCVA and VF in the first year RESTORE extension phase. These data provide further evidence for long-term safety and efficacy of RBZ treatment in DME...